Menu
Innovation Observatory > Reports > Drugs > Blinatumomab (Blincyto) for First Relapsed/Refractory, B-precursor, Acute Lymphoblastic Leukaemia, in Children and Adolescents

< Back

Blinatumomab (Blincyto) for First Relapsed/Refractory, B-precursor, Acute Lymphoblastic Leukaemia, in Children and Adolescents

Drugs

Cancer and Palliative Care

December 2017


linatumomab is a type of drug called a monoclonal antibody. Monoclonal antibodies work by seeking out cancer cells by looking for particular proteins on the cells’ surface. Blinatumomab is a new drug that is already used to treat ALL in adults and is currently being studied to see how well it works and whether it is safe to use in children and young people with ALL. If blinatumomab is licensed for use in the UK, it will offer a new treatment for paediatric patients with B-precursor ALL that have not responded to initial treatment (refractory) or has returned after initial successful treatment (relapsed).

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

Blinatumomab for ALL



Load More Related Posts
Get Alerts